MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.
MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.
- MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.
- Applications to the FDA for global phase III clinical trials are expected to take place in the second quarter of 2024.
- Megapro states that the diagnosis of focal liver lesion by contrast-enhanced MRI remained an important clinical needs globally.
- Therefore, MegaPro plans to further develop the MPB1523, nano-iron oxide MRI contrast agent, for its phase 3 study.